Pharmacy and Poisons Board

EMA Management Board: highlights of December 2023 meeting

Retrieved on: 
Monday, December 18, 2023

Work programme and budget for 2024The Board adopted EMA’s work programme for 2024, acknowledging that the Agency will continue to deliver on all its strategic priorities.EMA and…

Key Points: 


Work programme and budget for 2024The Board adopted EMA’s work programme for 2024, acknowledging that the Agency will continue to deliver on all its strategic priorities.EMA and…

Kingworld Medicines Expects 1H Profit Increased By 35%-40%

Retrieved on: 
Wednesday, August 2, 2023

HONG KONG, Aug 2, 2023 - (ACN Newswire) - Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year.

Key Points: 
  • HONG KONG, Aug 2, 2023 - (ACN Newswire) - Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year.
  • The Board attributes this profit increase to increased revenue and gross profit stemming from the distribution of imported branded pharmaceutical and healthcare products in China, with growth rates reaching approximately 30% to 35% and 15% to 20%, respectively.
  • Kingworld Medicines is a company specializing in the distribution of imported branded pharmaceutical and healthcare products in China.
  • Mr. Zhao Lisheng, Chairman of the Board of Kingworld Medicines Group, commented: "The Group's profit increase was mainly due to market recovery and the Group's employees' unremitting efforts, which adapted post-pandemic.

Vitrolife´s CEO to retire

Retrieved on: 
Monday, September 12, 2022

VALENCIA, Spain, Sept. 12, 2022 /PRNewswire/ --Today, Thomas Axelsson, CEO of Vitrolife AB (publ), informed the Board of Directors of his desire and intention to retire and be released from his position.

Key Points: 
  • VALENCIA, Spain, Sept. 12, 2022 /PRNewswire/ --Today, Thomas Axelsson, CEO of Vitrolife AB (publ), informed the Board of Directors of his desire and intention to retire and be released from his position.
  • Consequently, the process to find a new CEO to replace Thomas will immediately begin and will be led by Jon Sigurdsson, Chairman of the Board.
  • Thomas will remain as the CEO until the recruitment process is finalized.
  • "Since Thomas joined as the CEO in 2011, he has achieved a remarkable value creation and profitable growth.

IVD Medical Announces 2022 Interim Results

Retrieved on: 
Sunday, August 21, 2022

HONG KONG, Aug 22, 2022 - (ACN Newswire) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period").

Key Points: 
  • HONG KONG, Aug 22, 2022 - (ACN Newswire) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period").
  • Mr. Ho Kuk Sing, Chairman of IVD Medical, said, "In 2022, although the business environment of the medical industry has been tough under the pandemic, we have worked hard to overcome challenges and optimize our business operations.
  • The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by its equipment manufacturers, IVD Medical Equipment (Shanghai) Ltd. and Langmai Biotechnology (Shandong) Co., Ltd.
  • IVD Medical Holding Limited ("IVD Medical" or the "Group") is a leading distributor of IVD products in the PRC.

SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong, China

Retrieved on: 
Monday, July 4, 2022

This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.

Key Points: 
  • This study is led by a medical research team of the University of Hong Kong Clinical Trials Centre (HKU-CTC) in collaboration with Gleneagles.
  • The University of Hong Kong Clinical Trials Centre (HKU-CTC) is a one-stop clinical research management platform dedicated to facilitating the professional conduct of clinical research projects under HKUMed.
  • As Hong Kongs top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research.
  • Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

Kingworld Medicines Group Issues Positive Profit Alert for 2021

Retrieved on: 
Wednesday, March 23, 2022

HONG KONG, Mar 23, 2022 - (ACN Newswire) - Kingworld Medicines Group Limited (stock code: 01110.HK), a leading omni-channel enterprise providing greater health products and services in China, issued today a positive profit alert as it expects to record an approximately 155% to 160% increase in profit attributable to owners of the Company for 2021, as compared to RMB11.7 million for 2020.

Key Points: 
  • HONG KONG, Mar 23, 2022 - (ACN Newswire) - Kingworld Medicines Group Limited (stock code: 01110.HK), a leading omni-channel enterprise providing greater health products and services in China, issued today a positive profit alert as it expects to record an approximately 155% to 160% increase in profit attributable to owners of the Company for 2021, as compared to RMB11.7 million for 2020.
  • The positive profit alert was based on preliminary assessment of the unaudited consolidated management accounts of the Group for 2021 and information currently available to the Board.
  • Shenzhen Dong Di Xin Technology Company Limited, Kingworld Medicines' non-wholly owned subsidiary, is a manufacturer producing various medical devices including infrared thermometers.
  • Kingworld Medicines (stock code: 01110.HK) has devoted more than 20 years to developing a comprehensive greater health industrial supply chain system.

AMUNDI PRIME UK MID AND SMALL CAP - UCITS ETF DR - GBP (D): NOTICE TO SHAREHOLDERS

Retrieved on: 
Friday, November 12, 2021

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The Board decides to distribute Annual Dividends to each holder of distribution shares of AMUNDI PRIME UK MID AND SMALL CAP - UCITS ETF DR - GBP (D) according to the following calendar:
    Record date : November 15th, 2021
    Payment date : November 18th, 2021
    The paying agent is CACEIS Bank, Luxembourg Branch, 5 alle Scheffer, L-2520 Luxembourg.